Phase III trial of DaxibotulinumtoxinA for Upper Limb Spasticity
Latest Information Update: 17 May 2021
At a glance
- Drugs Daxibotulinumtoxin A (Primary)
- Indications Muscle spasticity
- Focus Registrational; Therapeutic Use
- Sponsors Revance Therapeutics
- 10 May 2021 According to a Revance Therapeutics media release, End-of-Phase 2 meeting with the FDA anticipated in the second half of 2021 for DaxibotulinumtoxinA for Injection for the treatment of adults with upper limb spasticity.
- 22 Feb 2021 According to a Revance Therapeutics, the company plan to schedule an end-of-Phase 2 meeting with the FDA prior to finalizing a Phase 3 program.
- 03 Jul 2020 New trial record